CombiGene AB (publ) reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was SEK 1.79 million compared to SEK 4.74 million a year ago. Net loss was SEK 6.29 million compared to net income of SEK 4.52 million a year ago. Basic loss per share from continuing operations was SEK 0.32 compared to basic earnings per share from continuing operations of SEK 0.23 a year ago. Diluted loss per share from continuing operations was SEK 0.32 compared to diluted earnings per share from continuing operations of SEK 0.23 a year ago.
For the six months, sales was SEK 3.96 million compared to SEK 16.14 million a year ago. Net loss was SEK 20.9 million compared to net income of SEK 1.83 million a year ago. Basic loss per share from continuing operations was SEK 1.06 compared to basic earnings per share from continuing operations of SEK 0.09 a year ago. Diluted loss per share from continuing operations was SEK 1.06 compared to diluted earnings per share from continuing operations of SEK 0.09 a year ago.